Table 3.
SGRQ sub-scale scores at 12 weeks
| Treatment | Treatment
|
Mean difference from tiotropium + placeboa
|
||
|---|---|---|---|---|
| n | Mean (SE) | Mean (SE) | 95% CI | |
| SGRQ total scoreb | ||||
| Tiotropium + placebo | 1,055 | 43.1 (0.33)c | ||
| Olodaterol + tiotropium | 1,039 | 41.2 (0.33)c | −1.9 (0.46)**** | −2.8, −1.0 |
| SGRQ symptom score | ||||
| Tiotropium + placebo | 1,059 | 51.4 (0.53) | ||
| Olodaterol + tiotropium | 1,043 | 47.6 (0.53) | −3.8 (0.75) | −5.2, –2.3 |
| SGRQ activity score | ||||
| Tiotropium + placebo | 1,061 | 60.5 (0.42) | ||
| Olodaterol + tiotropium | 1,046 | 58.7 (0.42) | −1.8 (0.59) | −2.9, −0.6 |
| SGRQ impact score | ||||
| Tiotropium + placebo | 1,060 | 30.5 (0.35) | ||
| Olodaterol + tiotropium | 1,041 | 29.3 (0.36) | −1.1 (0.50) | −2.1, −0.2 |
Notes:
a
A decrease in score reflects an improvement in health status
b
baseline SGRQ scores were 46.97 for tiotropium + placebo (n=1,123) and 47.68 for olodaterol + tiotropium (n=1,123)
c
the SGRQ total score change from baseline to week 12 was –4.128 units for tiotropium + placebo and –5.982 units for tiotropium + olodaterol.
****
P<0.0001.
Abbreviations: SGRQ, St George’s Respiratory Questionnaire; SE, standard error; CI, confidence interval.